4 recruiting, 1 active not recruiting, 1 unknown. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 4, Active not recruiting 1, Unknown 1 |
| Phase 2 | 3 | Recruiting 3 |
Follow Carboplatin Injection: new trials by email Literature Review of Carboplatin Injection trials Research Report on Carboplatin Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer SHR-1316 (sc) Injection, SHR-1316 Injection, Carboplatin Injection - Widespread Small Cell Lung Cancer | Phase 1 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 24 | 2025-06-16 | 2026-06-30 |
| SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer SHR-A1811, Adebelimab injection, Bevacizumab injection - Recurrent or Metastatic Cervical Cancer | Phase 1 / Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 100 | 2025-04-25 | 2025-06-06 |
| Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC JSKN016, Carboplatin, Furmonertinib Mesylate - Advanced Non-small Cell Lung Cancer | Phase 1 | Recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 288 | 2025-04-02 | 2026-03-30 |
| A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer SHR-A2102 for Injection, Adebrelimab Injection, Cisplatin injection - Advanced or Metastatic Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 248 | 2024-07-30 | 2025-12-23 |
| A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma LBL-024 for Injection, Etoposide Injection, Carboplatin Injection - Advanced Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 178 | 2023-12-08 | 2026-03-12 |
| Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma BEBT-908 for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Unknown | BeBetter Med Inc | 75 | 2023-12-01 | 2023-12-11 |
Carcinoma, Non-Small-Cell Lung (1) · Lymphoma, Large B-Cell, Diffuse (1) · Recurrence (1) · Uterine Cervical Neoplasms (1)
Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · BeBetter Med Inc (1) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd (1) · Nanjing Leads Biolabs Co.,Ltd (1) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1)
China (6)
Li Zhang (1) · Yuankai Shi, Phd (1)